Effects of Aceis on Peritoneal Protein Loss and Solute Transport in pd Patients

NCT01575652 | Completed Phase 4

• 1 other identifier: D-11-00212R1
• Study Type: interventional
• Target: 43
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objective of this study was to examine the effects of angiotensin converting enzyme inhibitors on peritoneal membrane transport, peritoneal protein loss, and proteinuria in peritoneal dialysis patients.

Conditions

Disorders Associated With Peritoneal Dialysis

Keywords

peritoneal dialysis; protein losses

Outcome Measures

Primary Outcomes (1)

• degree of peritoneal protein loss

  measurement of peritoneal protein loss after 6 months treatment of acei

  6 months

Study Arms (2)

ACE-I

ACTIVE COMPARATOR

Group using ACEIs

Other: Group using angiotensin converting enzyme inhibitor

ACE-I, 2

NO INTERVENTION

group not using ace-i

Other: Group not using angiotensin converting enzyme inhibitor

Interventions

Group using angiotensin converting enzyme inhibitor OTHER

Measurement of peritoneal protein loss level with use of ACEIs

Also known as: Perindopril, Lisinopril

ACE-I

Group not using angiotensin converting enzyme inhibitor OTHER

Measurement of peritoneal protein loss level without usage of ACEIs

ACE-I, 2

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• chronic peritoneal dialysis First paragraph.
• years
• no antihypertensive drug usage prior 12 months

You may not qualify if:

• usage of antihypertensives prior 12 months
• intolerance to the ace-i
• CAPD related peritonitis prior 6 months or during the study time
• history of malignant hypertension or hypertensive encephalopathy or cerebrovascular accident within the 6 months prior to the study
• chronic liver diseases
• recent acute illness and/or history of any overt chronic inflammatory disease

Sponsors & Collaborators

• Turkish Nephrology Association: lead

Related Publications (3)

• Rubin J, Adair C, Barnes T, Bower J. Dialysate flow rate and peritoneal clearance. Am J Kidney Dis. 1984 Nov;4(3):260-7. doi: 10.1016/s0272-6386(84)80103-1.

  PMID: 6496469 RESULT

• Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L. Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients. Nephron. 1986;42(2):133-40. doi: 10.1159/000183652.

  PMID: 3945351 RESULT

• Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996 Mar;11(3):498-506.

  PMID: 8671821 RESULT

Related Links

• fda approval of perindopril
• fda approval of lisinopril

MeSH Terms

Interventions

Perindopril; Lisinopril

Intervention Hierarchy (Ancestors)

Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Dipeptides; Oligopeptides; Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• taner basturk, MD

  Sisli Etfal training and Education Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: April 4, 2012
• First Posted: April 11, 2012
• Study Start: June 1, 2008
• Primary Completion: January 1, 2009
• Study Completion: January 1, 2009
• Last Updated: April 11, 2012

Record last verified: 2012-04